UCB today announced it will present 32 abstracts from its expansive epilepsies research program at the American Epilepsy Society (AES) Annual Meeting, December 6-10, 2024 (Los Angeles, California).
Commemorating a night full of soulful music, incredible theatricals, mouthwatering food and inspirational dialogues, UCB ...
It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
The board of United Community Banks, Inc. ( NYSE:UCB ) has announced that it will pay a dividend of $0.24 per share ...
“Earlier in the new century there’d been another entry in the annals of unforeseen classics: ‘More Cowbell,’ written by Will ...
The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here.
The U.S. Food and Drug Administration has approved UCB's Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate ...
UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...
This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback